Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients

Kinsella, Timothy J.; Glaubiger, Daniel; Diesseroth, Albert; Makuch, Robert W.; Waller, Brenda; Pizzo, P.Izzo; Glatstein, Eli

doi:10.1016/0360-3016(83)90368-1

Cited by 38 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Total body irradiation and single agent chemotherapy have been used as high-dose therapy but was relatively ineffective in controlling advanced disease [13][14][15][16][17][18]. However, TBI-containing myeloablative regimens have been reported to improve EFS of high-risk ES [1,[19][20][21][22]. Burdach et al reported a 6-year EFS of 45% for patients who received HDC and TBI followed by stem cell rescue compared to 2% for the historical control group of patients who were treated with chemotherapy only [8].…”

Section: Discussionmentioning

confidence: 99%

Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

Al-Faris

Harbi

Goia

et al. 2007

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

Al-Faris

Harbi

Goia

et al. 2007

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Treatment protocols used at the NCI for Ewing's sarcoma have been described previously. 19v24, 25 All protocols included radiation therapy to the entire bone and any soft tissue extension and chemotherapy with various combinations of vincristine, dactinomycin, doxorubicin, and cyclophosphamide. Based on the intensity of the combined therapy and for the purposes of statistical analyses, the protocols were grouped as early (Sl, S2, and S3; 1968 through 1972), mid (S4; 1972 through 1977), and recent (S5, S6, S7, S8, S9; 1977 through 1984).…”

Section: Clinical Correlationmentioning

confidence: 99%

Prognostic value of histopathology in ewing's sarcoma. Long-term follow-up of distal extremity primary tumors

Hartman

Triche

Kinsella

et al. 1991

Cancer

View full text Add to dashboard Cite

The pathologic material from 56 patients diagnosed initially as Ewing's sarcoma of the distal extremity and treated on National Cancer Institute protocols between 1968 and 1984 was reviewed and correlated with clinical outcome. Histologically, the tumors were categorized, based on recent pathologic criteria, into three diagnostic groups: (1) typical Ewing's sarcoma, (2) atypical Ewing's sarcoma, and (3) other (predominantly peripheral neuroepithelioma [PN]). Thirty-two patients (57%) had typical Ewing's, 13 (23%) were atypical, and 11 (20%) were in the "other" diagnostic category (seven [13%] PN, two primitive rhabdomyosarcoma, one primitive sarcoma of bone, and one synovial cell sarcoma). No cases of metastatic neuroblastoma, osteosarcoma, or lymphoma were found. Forty-five patients had localized disease at diagnosis; 11 had metastases. Patients with typical Ewing's sarcoma were less likely to have metastatic disease at the time of diagnosis. Only two of 32 patients with typical Ewing's sarcoma had metastases compared with nine of 24 patients in the two other groups. The pattern of relapse was also different in these other groups compared with typical Ewing's patients; five patients developed lymph node metastases and two patients developed brain metastases. Although the presence of metastatic disease at diagnosis was a strong negative prognostic factor, our histologic grouping was independently prognostic of clinical outcome in patients with localized disease. Patients with typical osseous Ewing's sarcoma had an improved overall survival (P2 = 0.03) and patients with other tumors (neither typical nor atypical Ewing's sarcoma) had a poorer disease-free survival (P2 = 0.02). Since no generally accepted histopathologic prognostic criteria exist for Ewing's sarcoma, the potential value of our proposed classification should be evaluated in a larger retrospective and a prospective study.

show abstract

“…Another treatment intensification strategy in Ewing's sarcoma is high-dose chemotherapy with autologous hematopoietic stem cell rescue (HDT) [113]. Because of the considerable toxicity of this approach, most studies investigate HDT for very high risk patients, most commonly those with metastatic disease at diagnosis, or following recurrence [77,[114][115][116]. A controlled, randomized study of HDT in Ewing's sarcoma has recently been undertaken in the www.TheOncologist.com framework of the EURO-E.W.I.N.G.…”

Section: Chemotherapymentioning

confidence: 99%

Ewing's Sarcoma Family of Tumors: Current Management

et al. 2006

View full text Add to dashboard Cite

show abstract

Intensive combined modality therapy including low-dose TBI in high-risk ewing's sarcoma patients

Cited by 38 publications

References 11 publications

Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

Prognostic value of histopathology in ewing's sarcoma. Long-term follow-up of distal extremity primary tumors

Ewing's Sarcoma Family of Tumors: Current Management

Contact Info

Product

Resources

About